Residency · Residency · Infectiousdisease

Antimicrobial Stewardship

Introduction

The Crisis of Antimicrobial Resistance

The Centers for Disease Control and Prevention estimates that 2.8 million antibiotic-resistant infections occur annually in the United States, resulting in more than 35,000 deaths. These figures, sobering as they are, represent only the domestic burden of a global crisis that the World Health Organization has designated as one of the top ten public health threats facing humanity. Between 30 and 50 percent of all inpatient antibiotic use is either unnecessary or inappropriate in terms of spectrum, dose, or duration, representing an enormous reservoir of modifiable prescribing that stewardship programs are designed to address.

The economic burden of antimicrobial resistance is estimated at 20 billion dollars in excess direct healthcare costs annually in the United States alone. Perhaps more alarming is the practical reality that the post-antibiotic era is no longer a theoretical construct. Pan-resistant organisms, including carbapenem-resistant Acinetobacter baumannii, carbapenem-resistant Enterobacterales, and extensively drug-resistant Pseudomonas aeruginosa, are encountered with increasing frequency in daily clinical practice, with therapeutic options sometimes reduced to a single agent or none at all.

Regulatory and Accreditation Requirements

The Joint Commission established an antimicrobial stewardship standard in 2017 mandating that all hospitals maintain a stewardship program. The Centers for Medicare and Medicaid Services followed in 2019 with a Condition of Participation requiring antibiotic stewardship programs in acute care hospitals. The CDC Core Elements of Hospital Antibiotic Stewardship Programs, updated in 2019, define the essential structural components: leadership commitment, accountability, pharmacy expertise, action, tracking, reporting, and education. These regulatory frameworks have elevated stewardship from a voluntary quality improvement initiative to a mandated component of hospital operations.

Core Stewardship Strategies

Prospective Audit and Feedback (PAF)

Prospective audit and feedback involves post-prescriptive review of antimicrobial orders with real-time feedback to prescribers. This strategy has consistently demonstrated itself to be the most effective stewardship intervention, reducing inappropriate antibiotic use by 20 to 40 percent across numerous institutional studies. The operational requirement for an effective PAF program is a dedicated team comprising an infectious disease physician and an infectious disease pharmacist who review targeted antimicrobial orders daily and communicate recommendations directly to the prescribing team.

The superiority of PAF over formulary restriction lies in its preservation of prescriber autonomy. Rather than preventing the prescription at the point of order entry, PAF allows the initial therapeutic decision to stand while providing expert input that guides optimization. This approach generates less prescriber frustration while achieving equal or greater reductions in inappropriate use. High-impact agents that should be targeted for PAF review include carbapenems, fluoroquinolones, anti-MRSA agents, and antifungals, as these represent the drug classes with the greatest potential for both collateral damage and unnecessary use.

Formulary Restriction and Preauthorization

Formulary restriction requires prospective approval before dispensing of designated restricted agents. This strategy achieves rapid and dramatic reductions in the use of targeted agents, with typical reductions of 30 to 50 percent when applied to agents such as meropenem. However, it carries the disadvantage of potentially causing the "squeezing the balloon" effect, in which prescribers shift to unrestricted agents that may be equally inappropriate, and it can introduce delays in therapy that are problematic for critically ill patients. Formulary restriction is best reserved for truly last-line agents such as ceftazidime-avibactam and daptomycin, or for agents with particularly high resistance-driving potential, where the barriers to prescribing serve as a necessary check on utilization.

Guideline-Based Clinical Pathways

Disease-specific order sets that embed evidence-based practices at the point of prescribing represent a powerful stewardship tool. By defaulting empiric antibiotic recommendations to regimens that align with the local antibiogram, and by incorporating automatic stop dates, these pathways reduce the cognitive burden on prescribers while ensuring that the most appropriate regimen is the easiest to order. A well-designed community-acquired pneumonia order set, for example, would default to ceftriaxone plus azithromycin with an automatic 5-day stop date, consistent with ATS/IDSA 2019 recommendations, and would require an active opt-out decision to prescribe broader coverage.

<image>A circular diagram showing the CDC Core Elements of Hospital Antibiotic Stewardship Programs. The center circle contains "Antimicrobial Stewardship Program." Seven surrounding circles connected by arrows include: "Hospital Leadership Commitment" (with budget icon), "Accountability" (with physician leader icon), "Pharmacy Expertise" (with ID pharmacist icon), "Action" (with prescription pad icon showing interventions), "Tracking" (with graph showing antibiotic usage metrics), "Reporting" (with dashboard icon), and "Education" (with teaching icon). Each element should have 2-3 bullet points of key requirements. Use a professional healthcare infographic style with blue and teal colors.</image>

Key Stewardship Interventions

IV-to-Oral Conversion

The transition from intravenous to oral antibiotic therapy represents one of the most impactful and readily implementable stewardship interventions. The criteria for safe IV-to-oral conversion include a functioning gastrointestinal tract, hemodynamic stability, clinical improvement, and an identified organism for which an oral agent with adequate bioavailability exists. The portfolio of high-bioavailability oral agents is more extensive than many prescribers appreciate:

Early IV-to-oral conversion is not merely a convenience measure; it represents an active harm-reduction strategy. PICC lines, which are required for prolonged intravenous therapy in the outpatient setting, carry a thrombosis rate of 2 to 5 percent and a central line-associated bloodstream infection rate of 1 to 2 percent, in addition to substantial costs and limitations on patient activity. Two landmark trials have expanded the envelope of acceptable oral step-down therapy. The POET trial, published in 2019, demonstrated that oral step-down for left-sided endocarditis was non-inferior to completion of intravenous therapy when strict eligibility criteria were met. The OVIVA trial, also published in 2019, showed similar non-inferiority for oral step-down in bone and joint infections. Together, these trials have fundamentally shifted the paradigm for diseases that were previously considered to mandate completion of intravenous therapy.

Duration of Therapy Optimization

Excessive duration of therapy represents the single most common stewardship opportunity and the intervention with the greatest aggregate impact. The evidence base supporting shorter treatment courses has grown dramatically.

Community-acquired pneumonia can be treated with 5 days of therapy rather than the traditional 7 to 10 days, as endorsed by the ATS/IDSA 2019 guidelines, with the simple criterion that therapy is discontinued when the patient has been clinically stable for at least 48 hours. Uncomplicated cystitis requires only 3 to 5 days depending on the agent used. Uncomplicated pyelonephritis requires 5 to 7 days with fluoroquinolones or 7 days with TMP-SMX. The STOP-IT trial demonstrated that 4 days of antibiotic therapy is adequate for intra-abdominal infections when source control has been achieved. Hospital-acquired and ventilator-associated pneumonia require only 7 days per ATS/IDSA 2016 guidelines.

The notable exception to the general trend toward shorter courses is Staphylococcus aureus bacteremia, which demands a minimum of 14 days for uncomplicated cases and 4 to 6 weeks for complicated disease. Procalcitonin-guided antibiotic discontinuation provides an objective biomarker-based strategy for shortening treatment duration, with the strongest evidence in respiratory infections and sepsis. Serial procalcitonin measurements with established stopping rules reduce antibiotic duration by 2 to 3 days without adverse outcomes, as demonstrated in the ProACT and PRORATA trials.

De-escalation

De-escalation, the narrowing of antimicrobial spectrum based on culture and susceptibility data, is a fundamental stewardship principle. The classic example involves transitioning from empiric vancomycin plus meropenem to targeted nafcillin monotherapy when blood cultures reveal MSSA. De-escalation also encompasses the removal of unnecessary double coverage, such as discontinuing metronidazole in a patient already receiving piperacillin-tazobactam, which provides adequate anaerobic coverage. Observational studies consistently demonstrate that de-escalation is safe and associated with improved outcomes, though the challenge remains when cultures are negative, requiring clinical judgment to guide spectrum narrowing without microbiologic data.

Antibiogram-Based Prescribing

The institutional antibiogram, updated annually, serves as the foundation for empiric therapy selection. Effective antibiograms should include unit-specific data differentiating ICU from floor isolates, as resistance patterns can vary substantially between these settings. The fundamental principle guiding empiric therapy for serious infections is that the selected regimen should provide at least 90 percent probability of covering the likely pathogens. When local E. coli susceptibility to ciprofloxacin falls to 75 percent, for example, fluoroquinolones should not be used as empiric first-line therapy for pyelonephritis. Weighted-incidence syndromic combination antibiograms offer a more sophisticated approach by matching empiric regimens to the probability of encountering specific organisms for defined clinical syndromes.

Penicillin Allergy Evaluation

Ten percent of hospitalized patients carry a penicillin allergy label, yet fewer than 1 percent have a true IgE-mediated allergy when formally tested. Patients labeled as penicillin-allergic receive more vancomycin, fluoroquinolones, and clindamycin, all of which carry broader spectra and more adverse effects than the beta-lactams they replace. Allergy de-labeling through skin testing followed by oral challenge reduces unnecessary alternative antibiotic use by approximately 50 percent. Pharmacist-led penicillin allergy assessment programs have proven highly effective and represent a high-yield stewardship intervention that every program should incorporate.

<image>A before-and-after comparison infographic illustrating common stewardship interventions. Left panel "Before Stewardship" shows: IV vancomycin + IV piperacillin-tazobactam for 14 days for a patient with cellulitis and cultures showing MSSA. Right panel "After Stewardship" shows the optimized approach: de-escalation to IV nafcillin on day 2 when cultures return, IV-to-oral switch to cephalexin on day 3 when clinically stable, total 5-day duration based on clinical response. Include metrics showing estimated cost savings, reduced IV days, avoided PICC line, and reduced C. difficile risk. Use green arrows showing improvement between panels.</image>

Stewardship in Special Contexts

Asymptomatic Bacteriuria (ASB)

The treatment of asymptomatic bacteriuria drives unnecessary antibiotic use and resistance without providing clinical benefit. Asymptomatic bacteriuria should not be treated in elderly patients, patients with indwelling urinary catheters, patients with diabetes, or patients in long-term care facilities. The only two populations in whom treatment of ASB is clearly indicated are pregnant women, in whom untreated bacteriuria carries a significant risk of pyelonephritis and preterm labor, and patients preparing for urologic surgery involving mucosal breach, in whom treatment reduces the risk of post-procedural bacteremia. Effective stewardship interventions for ASB include reflex urine culture cancellation protocols and diagnostic stewardship initiatives that restrict urine culture ordering to patients with documented urinary symptoms.

Diagnostic Stewardship

Diagnostic stewardship, ensuring the right test is ordered for the right patient at the right time, is a critically important complement to prescribing stewardship. Unnecessary testing generates unnecessary results that drive unnecessary treatment. Examples of diagnostic stewardship include avoiding C. difficile testing in patients receiving laxatives, avoiding blood cultures for low-risk patients without suspected bacteremia, and avoiding urine cultures in patients without urinary symptoms.

Rapid diagnostic platforms, including the BioFire BCID2 panel, Verigene, and Accelerate Pheno, have the potential to dramatically accelerate de-escalation by providing organism identification and preliminary resistance information hours to days faster than conventional culture methods. However, these platforms generate their greatest stewardship impact when paired with real-time notification to a stewardship pharmacist or infectious disease physician who can translate the result into an immediate prescribing intervention. MALDI-TOF mass spectrometry provides organism identification from positive blood cultures within 1 to 2 hours, compared to 24 to 48 hours with conventional methods.

Outpatient Stewardship

Outpatient prescriptions account for approximately 80 percent of human antibiotic use, making the outpatient setting the highest-volume target for stewardship intervention. The highest-impact targets include acute bronchitis, for which antibiotics are never indicated; sinusitis, where watchful waiting is appropriate for the first 10 days of symptoms; pharyngitis, where testing using Centor or McIsaac criteria should precede treatment; and uncomplicated UTI, where the shortest effective course should be prescribed. The delayed prescription strategy, in which patients are provided a prescription but counseled to fill it only if symptoms worsen or fail to improve, is effective for respiratory infections, with approximately 50 percent of patients never filling the prescription.

COVID-19 and Stewardship

The COVID-19 pandemic provided a powerful illustration of both the challenges and the importance of antimicrobial stewardship. Although the bacterial co-infection rate at hospital admission for COVID-19 was only 3 to 8 percent, more than 70 percent of hospitalized COVID-19 patients received empiric antibiotics during the early pandemic, reflecting a massive overprescribing response driven by clinical uncertainty. Key stewardship lessons from the pandemic include the utility of procalcitonin-guided de-escalation, the importance of avoiding azithromycin for "COVID pneumonia" when bacterial co-infection is not suspected, and the value of rapid respiratory panels in identifying non-bacterial etiologies.

Measuring Stewardship Outcomes

Process Metrics

The primary process metric for stewardship programs is days of therapy per 1000 patient-days, which is the standard metric reported through the NHSN Antibiotic Use module. Defined daily doses, the WHO-standardized metric, provide an alternative but are less clinically meaningful than days of therapy. Additional process metrics include the appropriateness of empiric therapy as measured by concordance with local guidelines, time to de-escalation, IV-to-oral conversion rates, and compliance with recommended therapy durations.

Outcome Metrics

Clostridioides difficile infection rates provide the most direct and consistently demonstrated link to antibiotic overuse, making them the most commonly tracked stewardship outcome. Resistance trends, reviewed through quarterly antibiogram analysis, provide a longer-term measure of stewardship impact. Mortality, length of stay, and readmission rates are important but more difficult to attribute directly to stewardship interventions due to extensive confounding. Cost savings represent a compelling argument for stewardship programs, with typical programs saving 200,000 to 900,000 dollars annually.

<image>A dashboard-style infographic showing key antimicrobial stewardship metrics displayed as a hospital quality dashboard. Include: (1) A line graph showing "DOT/1000 Patient-Days" trending over 12 months for broad-spectrum agents (carbapenems, fluoroquinolones, vancomycin) with a target line. (2) A bar chart showing "C. difficile cases per 10,000 patient-days" quarterly with downward trend. (3) A pie chart showing "Appropriateness of Empiric Therapy" (appropriate, suboptimal, inappropriate percentages). (4) A gauge meter showing "IV-to-PO Conversion Rate" at 68% with target of 80%. (5) A dollar sign icon showing annual cost savings. Use a modern clinical dashboard aesthetic with green for on-target metrics and amber/red for below-target.</image>

Key Clinical Pearls

• Prospective audit and feedback is the highest-yield stewardship intervention and should be the foundation of every program
• The single most impactful intervention is often shortening duration of therapy -- most infections are treated for too long
• Penicillin allergy de-labeling is a stewardship intervention with far-reaching benefits: reduced vancomycin use, fewer C. difficile infections, lower costs
• Treat the patient, not the culture: asymptomatic bacteriuria and colonization should not drive antibiotic prescriptions
• Diagnostic stewardship (preventing unnecessary cultures) is as important as prescribing stewardship -- you cannot treat a result you do not have
• Rapid molecular diagnostics have the greatest stewardship impact when coupled with real-time pharmacist or ID notification
• Every stewardship program needs both a physician and pharmacist champion -- this is the minimal effective structure

References

1. Barlam TF, Cosgrove SE, Abbo LM, et al. Implementing an antibiotic stewardship program: guidelines by the IDSA and SHEA. Clin Infect Dis. 2016;62(10):e51-e77.
2. CDC. Core Elements of Hospital Antibiotic Stewardship Programs. Atlanta, GA: US Department of Health and Human Services, CDC; 2019.
3. Iversen K, Ihlemann N, Gill SU, et al. Partial oral versus intravenous antibiotic treatment of endocarditis (POET). N Engl J Med. 2019;380(5):415-424.
4. Sawyer RG, Claridge JA, Nathens AB, et al. Trial of short-course antimicrobial therapy for intraabdominal infection (STOP-IT). N Engl J Med. 2015;372(21):1996-2005.
5. Tamma PD, Miller MA, Cosgrove SE. Rethinking how antibiotics are prescribed: incorporating the 4 moments of antibiotic decision making. JAMA. 2019;321(2):139-140.

Read this lecture as Markdown